Algorytm postępowania w leczeniu skojarzonym zaburzeń lipidowych na podstawie zaleceń ADA i PTD – spojrzenie diabetologa Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2011
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Cichocka, E., & Gumprecht, J. (2011). Algorytm postępowania w leczeniu skojarzonym zaburzeń lipidowych na podstawie zaleceń ADA i PTD – spojrzenie diabetologa . Medycyna Faktów , 4(4(13), 28-31. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2502
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Polskie Towarzystwo Diabetologiczne. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2011. Diabet. Prakt. 2011; 12(supl.): A1-A46.
2. ADA Management of dyslipidemia in adult with a diabetes. Diabetes Care 2011; 27 (supl. 1): S29-S40.
3. Stamler J., Vaccaro O., Neaton J.D.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 2(16): 434-444.
4. Haffner S.M., Lehto S., Ronnemaa T. et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998; 339(4): 229-234.
5. Dunn F.L.: Management of dyslipidemia in people with type 2 diabetes mellitus. Rev. Endocr. Metab. Disord. 2010; 11(1): 41-51.
6. Carey V., Bishop L., Laranjo N. et al.: Contribution of high plasma triglycerides and low high density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low density lipoprotein cholesterol control. Am. J. Cardiol. 2010; 106: 757-763.
7. Grundy S.M., Vega G.L., Yuan Z. et al.: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 2005 15; 95(4): 462-468.
8. Athyros V.G., Papageorgiou A.A., Athyrou V.V. et al.: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25(7): 1198-1202.
9. Durrington P.N., Tuomilehto J., Hamann A. et al.: Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res. Clin. Pract. 2004; 64(2): 137-151.
10. May H.T., Anderson J.L., Pearson R.R. et al.: Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am. J. Cardiol. 2008; 101(4): 486-489.
11. Keech A., Simes R.J., Barter P. et al.: FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849-1861.
12. ACCORD Study Group, Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R. 3rd, Leiter L.A., Linz P., Friedewald W.T., Buse J.B., Gerstein H.C., Probstfield J., Grimm R.H., Ismail-Beigi F., Bigger J.T., Goff D.C. Jr, Cushman W.C., Simons-Morton D.G., Byington R.P.: Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N. Engl. J. Med. 2010; 362: 1563-1574.
13. Brown B.G., Zhao X.Q., Chait A. et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001; 345: 1583-1592.
14. Grundy S.M., Vega G.L., McGovern M.E. et al.: Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. 2002; 162(14): 1568-76.
15. Davidson M.H., Stein E.A., Bays H.E. et al.: COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 2007; 29(7): 1354-1367.
16. Yokoyama M., Origasa H., Matsuzaki M. et al.: Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369(9567): 1090-1098.
17. Baigent C., Landray M.J., Reith C. et al.: SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-2192.
2. ADA Management of dyslipidemia in adult with a diabetes. Diabetes Care 2011; 27 (supl. 1): S29-S40.
3. Stamler J., Vaccaro O., Neaton J.D.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 2(16): 434-444.
4. Haffner S.M., Lehto S., Ronnemaa T. et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998; 339(4): 229-234.
5. Dunn F.L.: Management of dyslipidemia in people with type 2 diabetes mellitus. Rev. Endocr. Metab. Disord. 2010; 11(1): 41-51.
6. Carey V., Bishop L., Laranjo N. et al.: Contribution of high plasma triglycerides and low high density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low density lipoprotein cholesterol control. Am. J. Cardiol. 2010; 106: 757-763.
7. Grundy S.M., Vega G.L., Yuan Z. et al.: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 2005 15; 95(4): 462-468.
8. Athyros V.G., Papageorgiou A.A., Athyrou V.V. et al.: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25(7): 1198-1202.
9. Durrington P.N., Tuomilehto J., Hamann A. et al.: Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res. Clin. Pract. 2004; 64(2): 137-151.
10. May H.T., Anderson J.L., Pearson R.R. et al.: Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am. J. Cardiol. 2008; 101(4): 486-489.
11. Keech A., Simes R.J., Barter P. et al.: FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849-1861.
12. ACCORD Study Group, Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R. 3rd, Leiter L.A., Linz P., Friedewald W.T., Buse J.B., Gerstein H.C., Probstfield J., Grimm R.H., Ismail-Beigi F., Bigger J.T., Goff D.C. Jr, Cushman W.C., Simons-Morton D.G., Byington R.P.: Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N. Engl. J. Med. 2010; 362: 1563-1574.
13. Brown B.G., Zhao X.Q., Chait A. et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001; 345: 1583-1592.
14. Grundy S.M., Vega G.L., McGovern M.E. et al.: Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. 2002; 162(14): 1568-76.
15. Davidson M.H., Stein E.A., Bays H.E. et al.: COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 2007; 29(7): 1354-1367.
16. Yokoyama M., Origasa H., Matsuzaki M. et al.: Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369(9567): 1090-1098.
17. Baigent C., Landray M.J., Reith C. et al.: SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-2192.